Chronic Plaque Psoriasis Clinical Trials

72 clinical trials for Chronic Plaque Psoriasis across international registries, including 8 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• To Check Comparison of Apremilast and Methotrexate Efficacy in Patients With Moderate to Severe Plaque Psoriasis Presented to Tertiary Care Hospital — RECRUITING · PHASE1
• MULTICENTER, RANDOMIZED, PARALLEL-GROUP, DOUBLE-BLIND, PLACIEBO-CONTROLLED (12-17 YEARS) INCLUDING A SINGLE OPEN-LABEL ARM (6-11 YEARS) STUDY TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF CERTOLIZUMAB PEGOL (CZP) IN PEDIATRIC SUBJECTS WITH MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS (PSO) — RECRUITING
• A MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE SAFE AND EFFECTIVE USE OF THE PREFILLED SAFETY SYRINGES OR THE AUTO-INJECTOR FOR THE SUBCUTANEOUS SELF-INJECTION OF BIMEKIZUMAB SOLUTION BY SUBJECTS WITH MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS — RECRUITING
• A PHASE 3, MULTICENTER, RANDOMIZED, PLACEBO- AND ACTIVE COMPARATOR-CONTROLLED STUDY EVALUATING THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF SUBCUTANEOUSLY ADMINISTERED GUSELKUMAB FOR THE TREATMENT OF CHRONIC PLAQUE PSORIASIS IN PEDIATRIC SUBJECTS (¿6 TO <18 YEARS OF AGE) — RECRUITING · PHASE3
• A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, SECUKINUIMAB-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BIMEKIZUMAB IN ADULT SUBJECTS WITH MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS (PHASE 3B) — RECRUITING · PHASE3
• A MULTICENTER, RANDOMIZED, SUBJECT-BLIND, INVESTIGATOR-BLIND STUDY TO EVALUATE THE TIME COURSE OF PHARMACODYNAMIC RESPONSE, SAFETY AND PHARMACOKINETICS OF BIMEKIZUMAB IN ADULT SUBJECTS WITH MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS: PHASE 2A — RECRUITING · PHASE2
• A MULTICENTER, 48-WEEK, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF BIMEKIZUMAB IN ADULT SUBJECTS WITH MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS: PHASE 2B — RECRUITING · PHASE2
• A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, DOSE RANGING STUDY TO EVALUATE THE SAFETY, EFFICACY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF BINEKIZUMAB IN ADULT SUBJECTS WITH MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS: PHASE 2B — RECRUITING · PHASE2
• A One-year study to evaluate the effects and safety of CP-690,550 in patients with moderate to severe chronic plaque psoriasis — COMPLETED · PHASE3
• Study to evaluate safety and efficacy of different doses of Bimekizumab in patients with chronic plaque psoriasis. — COMPLETED · PHASE2
• A study to test the effectiveness and safety of GSK2586184 – a new oral medicine for chronic plaque psoriasis. — COMPLETED · PHASE2
• Study to evaluate the long-term safety, tolerability and efficacy of bimekizumab in patients with chronic plaque psoriasis. — COMPLETED · PHASE2
• Study to test efficacy, tolerability, safety and pharmacokinetics of Tofacitinib ointment in subjects with mild, moderate or severe chronic plaque psoriasis. — COMPLETED · PHASE2
• An Open Label Trial to Evaluate Efficacy and Safety of Roflumilast 0.3% Cream for Chronic Plaque and Nail Psoriasis — NOT_YET_RECRUITING · PHASE4
• A Study to Evaluate the Efficacy and Safety of Bimekizumab in Chinese Adult Study Participants With Moderate to Severe Plaque Psoriasis — COMPLETED · PHASE3
• Skin Transcriptional Profiles In Psoriatic Patients Under Adalimumab Biotherapy — COMPLETED · PHASE2
• Comparison of Methotrexate and Tofacitinib in Chronic Plaque Psoriasis — NOT_YET_RECRUITING · NA
• A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis — COMPLETED · PHASE3
• A Study With a Initial Treatment Period Followed by a Randomized-withdrawal Period to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis — COMPLETED · PHASE3
• A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis — COMPLETED · PHASE3
• A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis — COMPLETED · PHASE3
• A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Placebo and an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis — COMPLETED · PHASE3
• Efficacy and Safety Study of Tildrakizumab in the Treatment of Nail Psoriasis — COMPLETED · PHASE3
• A Study to Evaluate the Pharmacokinetics (PK), Pharmacodynamics (PD), and Safety of Bimekizumab in Patients With Chronic Plaque Psoriasis — COMPLETED · PHASE2
• A Phase 3, Multicenter, Randomized, Placebo- and Active Comparator-Controlled Study Evaluating the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Guselkumab for the Treatment of Chronic Plaque Psoriasis in Pediatric Participants (≥6 To <18 Years of Age) — TERMINATED · PHASE3
• Observational Study of Patients With Moderate to Severe Chronic Plaque Psoriasis — COMPLETED
• A Study to Evaluate the Safe and Effective Use of the Prefilled Safety Syringe or the Auto-injector for the Subcutaneous Self-injection of Bimekizumab Solution by Subjects With Moderate to Severe Chronic Plaque Psoriasis (PSO) — COMPLETED · PHASE3
• Open-Label Extension Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis — COMPLETED · PHASE3
• Chronic Plaque Psoriasis (Ps) Registry — COMPLETED
• Safety and Tolerability of Repeat Courses of IM Alefacept — COMPLETED · PHASE3
• Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis — COMPLETED · PHASE3
• Twin Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis — COMPLETED · PHASE3
• A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Patients With Chronic Plaque Psoriasis — COMPLETED · PHASE2
• A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Adult Patients With Chronic Plaque Psoriasis — COMPLETED · PHASE2
• Study to Evaluate Safety and Efficacy of Different Doses of Bimekizumab in Patients With Chronic Plaque Psoriasis — COMPLETED · PHASE2
• A Phase 2, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Belumosudil in Subjects With Moderate/Severe Chronic Plaque Psoriasis — COMPLETED · PHASE2
• A Study of Calcitriol BID Topical Treatment in Adolescents With Plaque Psoriasis — COMPLETED · PHASE2
• Study to Evaluate the Effect of Secukinumab Compared to Placebo on Aortic Vascular Inflammation in Subjects With Moderate to Severe Plaque Psoriasis — COMPLETED · PHASE4
• Safety and Efficacy of Secukinumab Compared to Etanercept in Subjects With Moderate to Severe, Chronic Plaque-Type Psoriasis — COMPLETED · PHASE3
• Study to Evaluate the Safety and Antipsoriatic Efficacy of BOS-475 in a Psoriasis Plaque Test — COMPLETED · PHASE1
• A PHASE 3, 8-WEEK, PARALLEL GROUP, DOUBLE BLIND, VEHICLE-CONTROLLED STUDY OF THE SAFETY AND EFFICACY OF ARQ-151 CREAM 0.3% ADMINISTERED QD IN SUBJECTS WITH CHRONIC PLAQUE PSORIASIS — COMPLETED · PHASE3
• Efficacy Study of CDP870 in Subjects With Chronic Plaque Psoriasis Who Are Candidate for Systemic Therapy and/or Phototherapy/Photochemotherapy — COMPLETED · PHASE2
• Study To Evaluate Safety And Efficacy Of PF-06700841 In Subjects With Moderate To Severe Plaque Psoriasis — COMPLETED · PHASE2
• The Effect Of Smoking Status Of The Patient On The Success Of Etanercept Therapy In Psoriasis — COMPLETED
• Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis — COMPLETED · PHASE3
• A MULTICENTER, OPEN-LABEL STUDY TO ASSESS THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF BIMEKIZUMB IN ADULT SUBJECTS WITH MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS (PHASE 3) — COMPLETED · PHASE3
• A PHASE 2B RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, MULTI-CENTER 12-WEEK STUDY WITH AN ADDITIONAL 40-WEEK FOLLOW-UP ASSESSMENT OF EFFICACY, SAFETY AND TOLERABILITY OF M1095 IN SUBJECTS WITH MODERATE TO SEVERE CHRONIC PLAQUE-TYPE PSORIASIS — COMPLETED · PHASE2
• A RANDOMIZED, DOUBLE-BLIND, PLACEBO AND ACTIVE CONTROLLED MULTICENTER TRIAL TO DEMONSTRATE EFFICACY OF SUBCUTANEOUS SECUKINUMAB COMPARED TO PLACEBOAND ETANERCEPT (IN A SINGLE-BLINDED ARM) AFTER TWELVE WEEKS OF TREATMENT, AND TO ASSESS THE SAFETY, TOLERABILITY, AND LONG-TERM EFFICACY IN SUBJECTS FROM 6 TO LESS THAN 18 YEARS OF AGE WITH SEVERE CHRONIC PLAQUE PSORIASIS — COMPLETED
• Phase II Efficacy Study Looking at a Single-dose of One of Three Dose Levels of AIN457 in Patients With Chronic Plaque-type Psoriasis — COMPLETED · PHASE2
• A MULTICENTER, 48-WEEK, OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY, TOLERABILITY AND EFFICACY OF BIMEKIZUMAB IN ADULT SUBJECTS WITH MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS — COMPLETED

Refine this search